SCHEMBL27488807

SCHEMBL27488807

CC1(C)NC(=O)CNC1C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.33
HDAC1 Q13547 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
ARG1 P05089 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
APLNR P35414 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432004 0.74 HTT (0.35) HTTARG1EGLN1APLNR
SCHEMBL3939441 0.68 HTT (0.38) HTTHDAC1SMN1; SMN2CYP2C19APLNR
SCHEMBL7271734 0.68 HTT (0.38) HTTHDAC1SMN1; SMN2CYP2C19APLNR
SCHEMBL7994230 0.65 SLC1A2 (0.37) HTTAPLNR
SCHEMBL10943324 0.64
SCHEMBL18586584 0.61 CYP3A4 (0.46) HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19
SCHEMBL24633711 0.61
SCHEMBL38655259 0.61
SCHEMBL11763607 0.60 HTT (0.42) HTT
SCHEMBL10345485 0.60 HTT (0.41) HTTARG1APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1207289-C Metalloprotease inhibitors, pharmaceutical compositions containing them and their use as medicaments, process and intermediates for their preparation AGOURON PHARMA (US) 2005-06-22 CN disclosed
CN-1542002-A Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation ������ҩ�����޹�˾ 2004-11-03 CN disclosed
CN-1207734-A Metalloprotease inhibitors, pharmaceutical compositions containing them and their use as medicaments, process and intermediates for their preparation AGOURON PHARMA (US) 1999-02-10 CN disclosed